Ptc Therapeutics (PTCT) Gains from Investment Securities (2012 - 2025)

Ptc Therapeutics' Gains from Investment Securities history runs 14 years deep, the most recent figure standing at -$800000.0 for Q1 2025.

• On a quarterly basis, Gains from Investment Securities fell 700.0% year-over-year to -$800000.0 in Q1 2025; TTM through Dec 2025 was -$800000.0, a 82.12% increase from a year earlier, with the FY2025 full-year figure at -$800000.0, up 82.12% from the prior year.
• Gains from Investment Securities climbed to -$800000.0 in Q1 2025 per PTCT's latest filing, from -$10.2 million in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $10.8 million in Q3 2021 and bottomed at -$128.9 million in Q2 2023.
• The 5-year median for Gains from Investment Securities is -$100000.0 (2024), against an average of -$9.4 million.
• Biggest YoY gain for Gains from Investment Securities was 152.07% in 2022; the steepest drop was 11800.0% in 2022.
• Year by year, Gains from Investment Securities stood at -$12.1 million in 2021, then surged by 152.07% to $6.3 million in 2022, then plunged by 142.86% to -$2.7 million in 2023, then plunged by 276.85% to -$10.2 million in 2024, then surged by 92.14% to -$800000.0 in 2025.
• Per Business Quant, the three latest PTCT Gains from Investment Securities figures stand at -$800000.0 (Q1 2025), -$10.2 million (Q4 2024), and $700000.0 (Q3 2024).